Navigation Links
Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
Date:5/17/2010

QUEBEC CITY, May 17 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris stated, "We are very pleased with AEZS-108 gaining orphan medicinal product designation for ovarian cancer from European authorities, especially after having been recently granted orphan-drug designation by the FDA. This means that with both these orphan designations, AEZS-108 would be provided with extra market exclusivity protection in Europe as well as in the United States for the treatment of ovarian cancer. We now look forward to reporting the final results from our ongoing European Phase 2 study in ovarian and endometrial cancer, later this year."

About Orphan Medicinal Product Designation

Orphan medicinal product designation is granted by the European Commission, following a positive opinion from the COMP, to a medicinal product that is intended for the diagnosis, prevention or treatment of a life-threatening or a chronically debilitating condition affecting not more than five in 10,000 persons in the Community when the application for designation is submitted.

Orphan medicinal produc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... NewYork (PRWEB) September 01, 2014 ... Biotech and Diagnostics report provides comprehensive understanding and ... agreements entered into by the worlds leading life ... understand and analysis of how and why companies ... of a prospective partner’s negotiated deals terms provides ...
(Date:8/31/2014)... Wockhardt Limited today announces a major boost ... when two of its drugs, WCK 771 and WCK ... status from U.S. Food & Drug Administration (FDA).  QIDP ... which have a high degree of unmet need in ... Control (a top U.S. government health and safety body). ...
(Date:8/31/2014)... Available spectra is similar for all ... cultivation of a wide range of plants. The ... proven patented and pending wide spectrum technology. The ... critical applications in contrast to growth spectra made ... have a large variety of differently sized and ...
(Date:8/31/2014)... 2014 Market Research Report ... and in-depth research report on the Polyacrylamide ... including Polyacrylamide definition, classification, application, and industry ... This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic ...
Breaking Biology Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3
... Corporation,(NYSE: WAT ) today published a ... in,infant formula and liquid milk as outlined ... Technology (M.O.S.T.). The new method uses,Waters(R) ACQUITY(R) ... spectrometry (UPLC/MS/MS) operated in Multiple Reaction,Monitoring (MRM) ...
... Institutes of Health (NIH) have demonstrated for the first ... to muscles can restore voluntary movement in monkeys whose ... have promising implications for the quarter of a million ... others with paralyzing neurological diseases, although clinical applications are ...
... Researchers have created a new material that overcomes two ... all the energy contained in sunlight, and generates electrons ... , Ohio State University chemists and their colleagues ... titanium to create the hybrid material. , "There are ...
Cached Biology Technology:Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of China's Ministry of Science and Technology 2Scientists restore movement to paralyzed limbs through artificial brain-muscle connections 2Scientists restore movement to paralyzed limbs through artificial brain-muscle connections 3New solar energy material captures every color of the rainbow 2
(Date:9/1/2014)... nucleotidethe basic building block of DNAcould initiate fragile X syndrome, the ... The Journal of Cell Biology . ... gene on the X chromosome called fragile X mental retardation ... 360 men carry a so-called premutation, in which a series of ... is slightly longer than normal. These repeats are prone to even ...
(Date:9/1/2014)... electron microscopy revealed the presence of tiny blob-like structures ... scientists still don,t know what they do even ... to be crucial to the life of a cell, ... treatment., In the Journal of Cell Biology , ... various backgrounds, from biophysics to cell biology, to focus ...
(Date:9/1/2014)... nocturnal animals, bats are perfectly adapted to a life without ... the reflected echoes to measure distance to obstacles or prey. ... echo delays. A study carried out by researchers at Technische ... this map dynamically adapts to external factors. , ... flies in too close to an object, the number of ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Scientists call for investigation of mysterious cloud-like collections in cells 2Zooming in for a safe flight 2
... PITTSBURGH, Jan. 3 Mice bred to age too quickly ... scientists at the University of Pittsburgh School of Medicine injected ... of young, healthy animals. Instead of becoming infirm and dying ... cells improved their health and lived two to three times ...
... line of attack against pancreatitis and pancreatic cancer is ... substantial new funding from the Medical Research Council (MRC). ... digestion turn on the pancreas itself. Chronic pancreatitis increases ... five-year survival rate of all common cancers in the ...
... kind, researchers at Queens College and Mount Sinai School ... and maternal gestational diabetes together may cause a 14-fold ... six year olds. The data are published in the ... Adolescent Medicine , one of the JAMA/Archives journals. ...
Cached Biology News:Pitt: A shot of young stem cells made rapidly aging mice live longer and healthier 2New stage in fighting pancreatic cancer 2Gestational diabetes and low socioeconomic status raise risk of ADHD in children 2
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Biology Products: